23 Jul, 2026
According to Straits Research, the global immunoassay market was valued at USD 28.29 billion in 2025 and is projected to grow from USD 29.52 billion in 2026 to USD 42.43 billion by 2034, registering a CAGR of 4.64% during the forecast period (2026–2034).
Growing adoption of automated diagnostic systems, advancements in immunoassay technologies, and expanding applications in clinical diagnostics and research are key factors driving market growth.
The immunoassay market is expanding as healthcare providers increasingly rely on highly sensitive diagnostic tools for the early detection and monitoring of diseases. Immunoassays play a vital role in diagnosing infectious diseases, cancer, autoimmune disorders, endocrine conditions, cardiovascular diseases, and allergies by detecting specific biomarkers with high accuracy.
The growing adoption of automated analyzers, multiplex testing, artificial intelligence (AI)-enabled diagnostic platforms, and point-of-care testing is improving laboratory efficiency and reducing turnaround times. In addition, increasing investments in personalized medicine, pharmaceutical research, and biomarker discovery are creating new opportunities for immunoassay manufacturers. The market is also benefiting from rising healthcare expenditure, expanding diagnostic laboratory networks, and increasing awareness of preventive healthcare. Although high equipment costs and stringent regulatory requirements remain challenges, continuous technological innovation and expanding diagnostic applications are expected to support sustained market growth throughout the forecast period.
North America dominated the global immunoassay market in 2025, accounting for 46.43% of the total revenue. The region's leadership is driven by advanced healthcare infrastructure, a high prevalence of chronic diseases, strong research and development investments, and the widespread adoption of advanced diagnostic technologies.
Asia-Pacific is expected to register the fastest growth during the forecast period, with a CAGR of 5.9%. The region is benefiting from rising healthcare expenditure, increasing cases of chronic and infectious diseases, expanding access to diagnostic services, and supportive government initiatives in countries such as China, India, and Japan.
sales@straitsresearch.com